VANCOUVER, British Columbia, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“ Aquinox ”) (NASDAQ: AQXP ), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will report its financial results for the second quarter ending June 30, 2016 and will provide a general business update on Thursday, August 4, 2016 after U.S. financial markets close. Aquinox will host a conference call and live audio webcast on Thursday, August 4, 2016 at 4:30 PM (ET) / 1:30 PM (PT).
Conference Call and Webcast Details: Date: Thursday, August 4 th , 2016 Time: 4:30 PM (ET) / 1:30 PM (PT) Toll-free: (866) 357-7878 International: (315) 625-3088 Conference ID: 54900899 Webcast URL: http://edge.media-server.com/m/p/ff6xquaz
The live webcast may be accessed through the " Events & Presentations " page in the " Investor Relations " section of the company's website at www.aqxpharma.com .
The archived webcast will also be available on Aquinox 's website approximately two hours after the event and will be available for replay for at least 30 days after the event.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. With a successful Phase 2 clinical trial completed in 2015, Aquinox plans to initiate a Phase 3 trial in 2016 with AQX-1125 for treatment of IC/BPS. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com .
Investor Contact Info: Brendan Payne Senior Manager, Investor Relations Aquinox Pharmaceuticals, Inc. 604.629.9223 Ext. 109 ir@aqxpharma.com
Gitanjali Ogawa Vice President The Trout Group 646-378-2949 Gogawa@troutgroup.com